Posted On: 11/11/2014 2:53:34 PM
Post# of 74544
ABBV Volume Alert - ABBV 64.18 Abbvie Inc. Common Stock $ABBV Hit a high of 64.20 Currently 11:15 Last price 64.18 +0.39 +0.61% With a day low of 63.60 and a current volume of 1,755,526.
ABBV Abbvie Inc. Common Stock Recent Headline News
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - 48 mins ago
SHPG: 201.60 (+0.62), PFE: 30.25 (+0.05), AZN: 74.27 (+1.06), ABBV: 63.63 (-0.16), WAG: 67.27 (-0.51)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 108.50 (+1.48), ACHN: 12.43 (-0.42), MRK: 59.23 (+0.42), ABBV: 63.63 (-0.16), BMY: 58.68 (-0.13)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), ACHN: 12.43 (-0.42), CNAT: 7.07 (+0.01), MRK: 59.23 (+0.42), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.68 (-0.13), ENTA: 43.13 (-1.01)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 117.42 (+0.48), GILD: 108.50 (+1.48), MRK: 59.23 (+0.42), DNDN: 0.15 (-0.03), AZN: 74.27 (+1.06), TEVA: 58.20 (+0.16), ABBV: 63.63 (-0.16), GSK: 45.84 (+0.68), BMY: 58.68 (-0.13), NVS: 92.63 (unch)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 384.94 (-2.33), YHOO: 48.87 (-0.54), AMZN: 311.04 (+5.93), BIIB: 323.82 (-4.05), VRTX: 117.42 (+0.48), FEYE: 32.98 (+0.59), LNKD: 229.54 (+0.29), EBAY: 54.22 (+0.33), GILD: 108.50 (+1.48), AMGN: 162.05 (-1.04), ABBV: 63.63 (-0.16), REGN: 399.10 (+13.13), CELG: 107.58 (-0.43)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), ACHN: 12.42 (-0.43), CNAT: 7.07 (+0.01), MRK: 59.23 (+0.42), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.68 (-0.13), ENTA: 43.13 (-1.01)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), ACHN: 12.42 (-0.43), CNAT: 7.07 (+0.01), MRK: 59.23 (+0.42), LGND: 57.05 (+1.37), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.68 (-0.13), ENTA: 43.13 (-1.01)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), ACHN: 12.43 (-0.42), CNAT: 7.07 (+0.01), LGND: 57.05 (+1.37), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.68 (-0.13), ENTA: 43.13 (-1.01)
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014
PR Newswire - Tue Nov 11, 8:00AM CST
AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014.
ABBV: 63.63 (-0.16), ENTA: 43.13 (-1.01)
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014
PR Newswire - Tue Nov 11, 7:00AM CST
AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved sustained virologic response rates at 12 weeks post-treatment (SVR12) after taking AbbVie's investigational treatment with ribavirin (RBV). Additionally, 90.9 percent of patients who were new to therapy achieved SVR12 (n=40/44) after taking the treatment without RBV. These data will be presented today during a poster session at The Liver Meeting® 2014.
ABBV: 63.63 (-0.16), ENTA: 43.13 (-1.01)
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 323.82 (-4.05), RPRX: 9.70 (+0.48), ABBV: 63.63 (-0.16), AMAG: 34.93 (+0.02)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 323.82 (-4.05), GILD: 108.50 (+1.48), SHPG: 201.66 (+0.68), ABBV: 63.63 (-0.16), CELG: 107.58 (-0.43)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.77 (+0.53), GILD: 108.50 (+1.48), MRK: 59.23 (+0.42), ABBV: 63.63 (-0.16)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 195.77 (+0.53), EBS: 24.51 (+0.56), ABAX: 53.55 (+0.61), ABBV: 63.63 (-0.16)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), ACHN: 12.43 (-0.42), MRK: 59.23 (+0.42), ABBV: 63.63 (-0.16), BMY: 58.67 (-0.14)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.50 (+1.48), ACHN: 12.43 (-0.42), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), CNAT: 7.07 (+0.01), MRK: 59.24 (+0.43), LGND: 57.05 (+1.37), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.67 (-0.14), ENTA: 43.13 (-1.01)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 108.50 (+1.48), MRK: 59.24 (+0.43), ABBV: 63.63 (-0.16)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), CNAT: 7.07 (+0.01), MRK: 59.24 (+0.43), LGND: 57.05 (+1.37), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.67 (-0.14), ENTA: 43.13 (-1.01)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), CNAT: 7.07 (+0.01), MRK: 59.24 (+0.43), LGND: 57.05 (+1.37), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.67 (-0.14), ENTA: 43.13 (-1.01)
ABBV Abbvie Inc. Common Stock Recent Headline News
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - 48 mins ago
SHPG: 201.60 (+0.62), PFE: 30.25 (+0.05), AZN: 74.27 (+1.06), ABBV: 63.63 (-0.16), WAG: 67.27 (-0.51)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 108.50 (+1.48), ACHN: 12.43 (-0.42), MRK: 59.23 (+0.42), ABBV: 63.63 (-0.16), BMY: 58.68 (-0.13)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), ACHN: 12.43 (-0.42), CNAT: 7.07 (+0.01), MRK: 59.23 (+0.42), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.68 (-0.13), ENTA: 43.13 (-1.01)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 117.42 (+0.48), GILD: 108.50 (+1.48), MRK: 59.23 (+0.42), DNDN: 0.15 (-0.03), AZN: 74.27 (+1.06), TEVA: 58.20 (+0.16), ABBV: 63.63 (-0.16), GSK: 45.84 (+0.68), BMY: 58.68 (-0.13), NVS: 92.63 (unch)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 384.94 (-2.33), YHOO: 48.87 (-0.54), AMZN: 311.04 (+5.93), BIIB: 323.82 (-4.05), VRTX: 117.42 (+0.48), FEYE: 32.98 (+0.59), LNKD: 229.54 (+0.29), EBAY: 54.22 (+0.33), GILD: 108.50 (+1.48), AMGN: 162.05 (-1.04), ABBV: 63.63 (-0.16), REGN: 399.10 (+13.13), CELG: 107.58 (-0.43)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), ACHN: 12.42 (-0.43), CNAT: 7.07 (+0.01), MRK: 59.23 (+0.42), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.68 (-0.13), ENTA: 43.13 (-1.01)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), ACHN: 12.42 (-0.43), CNAT: 7.07 (+0.01), MRK: 59.23 (+0.42), LGND: 57.05 (+1.37), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.68 (-0.13), ENTA: 43.13 (-1.01)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), ACHN: 12.43 (-0.42), CNAT: 7.07 (+0.01), LGND: 57.05 (+1.37), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.68 (-0.13), ENTA: 43.13 (-1.01)
AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014
PR Newswire - Tue Nov 11, 8:00AM CST
AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1) co-infection (TURQUOISE-I) and liver transplant recipients (CORAL-I) at The Liver Meeting®2014.
ABBV: 63.63 (-0.16), ENTA: 43.13 (-1.01)
AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014
PR Newswire - Tue Nov 11, 7:00AM CST
AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent of genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49) achieved sustained virologic response rates at 12 weeks post-treatment (SVR12) after taking AbbVie's investigational treatment with ribavirin (RBV). Additionally, 90.9 percent of patients who were new to therapy achieved SVR12 (n=40/44) after taking the treatment without RBV. These data will be presented today during a poster session at The Liver Meeting® 2014.
ABBV: 63.63 (-0.16), ENTA: 43.13 (-1.01)
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 323.82 (-4.05), RPRX: 9.70 (+0.48), ABBV: 63.63 (-0.16), AMAG: 34.93 (+0.02)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 323.82 (-4.05), GILD: 108.50 (+1.48), SHPG: 201.66 (+0.68), ABBV: 63.63 (-0.16), CELG: 107.58 (-0.43)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.77 (+0.53), GILD: 108.50 (+1.48), MRK: 59.23 (+0.42), ABBV: 63.63 (-0.16)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 195.77 (+0.53), EBS: 24.51 (+0.56), ABAX: 53.55 (+0.61), ABBV: 63.63 (-0.16)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), ACHN: 12.43 (-0.42), MRK: 59.23 (+0.42), ABBV: 63.63 (-0.16), BMY: 58.67 (-0.14)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.50 (+1.48), ACHN: 12.43 (-0.42), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), CNAT: 7.07 (+0.01), MRK: 59.24 (+0.43), LGND: 57.05 (+1.37), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.67 (-0.14), ENTA: 43.13 (-1.01)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 108.50 (+1.48), MRK: 59.24 (+0.43), ABBV: 63.63 (-0.16)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), CNAT: 7.07 (+0.01), MRK: 59.24 (+0.43), LGND: 57.05 (+1.37), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.67 (-0.14), ENTA: 43.13 (-1.01)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.83 (+0.01), GILD: 108.50 (+1.48), CNAT: 7.07 (+0.01), MRK: 59.24 (+0.43), LGND: 57.05 (+1.37), RGLS: 20.20 (-0.71), ABBV: 63.63 (-0.16), BMY: 58.67 (-0.14), ENTA: 43.13 (-1.01)
(0)
(0)Scroll down for more posts ▼
